Top

Published in:

01-07-2015 | Interventional

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

Authors: Julius Chapiro, Rafael Duran, MingDe Lin, Rüdiger Schernthaner, David Lesage, Zhijun Wang, Lynn Jeanette Savic, Jean-François Geschwind

Published in: European Radiology | Issue 7/2015

Abstract

Objectives

This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT).

Methods

This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR).

Results

Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4).

Conclusion

The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis.

Key Points

• Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible.

• Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival.

• Volumetric tumour response assessment shows advantages over 1D and 2D techniques.

• Enhancement-based MR response assessment is preferable to size-based measurements.

Available only for authorised users

Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128PubMedCrossRef

Engstrom PF, Arnoletti JP, Benson AB 3rd et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 7:778–831PubMed

Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC (2011) Colorectal liver metastases. Int J Surg Oncol 2011:285840PubMedCentralPubMed

Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047PubMedCrossRef

Memon K, Lewandowski RJ, Riaz A, Salem R (2012) Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Curr Treat Options Oncol 13:403–415PubMedCrossRef

Albert M, Kiefer MV, Sun W et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117:343–352PubMedCrossRef

Benson AB 3rd, Geschwind JF, Mulcahy MF et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49:3122–3130PubMedCrossRef

Hong K, McBride JD, Georgiades CS et al (2009) Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 20:360–367PubMedCrossRef

Kemeny NE, Niedzwiecki D, Hollis DR et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403PubMedCrossRef

10.

Gonzalez-Guindalini FD, Botelho MP, Harmath CB et al (2013) Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 33:1781–1800PubMedCrossRef

11.

Laubender RP, Lynghjem J, D'Anastasi M et al (2014) Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm. Eur Radiol 24:1521–1528PubMedCrossRef

12.

Huppert P, Wenzel T, Wietholtz H (2014) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol 37:154–164PubMedCrossRef

13.

Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33:2077–2083PubMed

14.

Tohme S, Sukato D, Nace GW et al (2014) Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB (Oxford). doi:10.1111/hpb.12307

15.

Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–856, discussion 856–847PubMedCrossRef

16.

Akhlaghpoor S, Aziz-Ahari A, Amoui M, Tolooee S, Poorbeigi H, Sheybani S (2012) Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. World J Gastroenterol 18:5249–5259PubMedCentralPubMed

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

18.

Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef

19.

Janne d'Othee B, Sofocleous CT, Hanna N et al (2012) Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol 23:153–163PubMedCrossRef

20.

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRef

21.

Riaz A, Memon K, Miller FH et al (2011) Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 54:695–704PubMedCentralPubMedCrossRef

22.

Bonekamp D, Bonekamp S, Halappa VG et al (2013) Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. doi:10.1016/j.ejrad.2013.11.016 PubMedCentralPubMed

23.

Heijmen L, Ter Voert EE, Nagtegaal ID et al (2013) Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 23:748–756PubMedCrossRef

24.

Tam HH, Collins DJ, Brown G et al (2013) The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. Br J Radiol 86:20130281PubMedCentralPubMedCrossRef

25.

Lin M, Pellerin O, Bhagat N et al (2012) Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol 23:1629–1637PubMedCentralPubMedCrossRef

26.

Mitchell DG, Bruix J, Sherman M, Sirlin CB (2014) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, consensus of the LI-RADS Management Working Group and future directions. Hepatology. doi:10.1002/hep.27304 PubMed

27.

Santillan CS, Tang A, Cruite I, Shah A, Sirlin CB (2014) Understanding LI-RADS: a primer for practical use. Magn Reson Imaging Clin N Am 22:337–352PubMedCrossRef

28.

Bogaerts J, Ford R, Sargent D et al (2009) Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 45:248–260PubMedCrossRef

29.

Kim BK, Kim SU, Kim MJ et al (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511PubMedCrossRef

30.

Tacher V, Lin M, Chao M et al (2013) Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol 20:446–452PubMedCentralPubMedCrossRef

31.

Chapiro JWL, Lin M et al (2014) A radiological-pathological analysis of contrast-enhanced and diffusion-weighted MRI in patients with HCC after TACE – testing the diagnostic accuracy of 3D quantitative image analysis. Radiology 273:746–758PubMedCentralPubMedCrossRef

32.

Pellerin O, Lin M, Bhagat N, Ardon R, Mory B, Geschwind JF (2013) Comparison of semi-automatic volumetric VX2 hepatic tumor segmentation from cone beam CT and multi-detector CT with histology in rabbit models. Acad Radiol 20:115–121PubMedCentralPubMedCrossRef

33.

Kim S, Mannelli L, Hajdu CH et al (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355PubMedCrossRef

34.

Wagner M, Doblas S, Daire JL et al (2012) Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 264:464–472PubMedCrossRef

35.

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214PubMedCrossRef

36.

Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer 89:605–611PubMedCentralPubMedCrossRef

37.

Hipps D, Ausania F, Manas DM, Rose JD, French JJ (2013) Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg 2013:570808PubMedCentralPubMedCrossRef

38.

Kekelidze M, D'Errico L, Pansini M, Tyndall A, Hohmann J (2013) Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol 19:8502–8514PubMedCentralPubMedCrossRef

39.

Koh DM, Brown G, Meer Z, Norman AR, Husband JE (2007) Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AJR Am J Roentgenol 188:W154–W161PubMedCrossRef

40.

Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S et al (2013) Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology 266:502–513PubMedCrossRef

41.

Wang Z, Lin M, Lesage D et al (2014) Three-dimensional evaluation of Lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol 21:393–399PubMedCentralPubMedCrossRef

42.

Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331PubMedCentralPubMedCrossRef

43.

Huppert P, Wenzel T, Wietholtz H (2013) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. doi:10.1007/s00270-013-0632-0 PubMed

44.

Jakobs TF, Hoffmann RT, Dehm K et al (2008) Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187–1195PubMedCrossRef

45.

Sato KT, Omary RA, Takehana C et al (2009) The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol 20:1564–1569PubMedCrossRef

46.

Fiorentini G, Aliberti C, Mulazzani L et al (2014) Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res 34:575–584PubMed

47.

Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver metastases. Radiology 266:407–430PubMedCrossRef

48.

Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858PubMedCrossRef

49.

Rosenbaum CE, Verkooijen HM, Lam MG et al (2013) Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med 54:1890–1895PubMedCrossRef

50.

Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS (2014) Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol 25:256–265PubMedCrossRef

Title: Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver
Authors: Julius Chapiro
Rafael Duran
MingDe Lin
Rüdiger Schernthaner
David Lesage
Zhijun Wang
Lynn Jeanette Savic
Jean-François Geschwind
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 7/2015
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3595-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 7/2015

Are novel non-invasive imaging techniques needed in patients with suspected prosthetic heart valve endocarditis? A systematic review and meta-analysis

Biased visualization of hypoperfused tissue by computed tomography due to short imaging duration: improved classification by image down-sampling and vascular models

Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase 18 F-FDG PET/CT

CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas

Sub-milliSievert (sub-mSv) CT colonography: a prospective comparison of image quality and polyp conspicuity at reduced-dose versus standard-dose imaging

Opportunistic screening for osteoporosis on routine computed tomography? An external validation study